Hygiene and Health: Are We Too Clean?

The needle-free nasal spray, if approved, would be the first new administration method for epinephrine in young children in 35 years.

Severe outcomes may ensue in a high percentage of patients. The authors discuss the consequences in this brief podcast.

neffy (epinephrine nasal spray) is the first alternative to epinephrine administered by autoinjector or syringe and is comparable in efficacy to the gold standard.

PK data from a self-administration study are comparable to those seen following administration by a clinician and Tmax equal at 15 minutes.

Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.

Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.